Earnings are still in focus with FedEx, Macy's, and Lululemon all reporting in the coming days.
Bloomberg's Nathan Hager previews the numbers with Denitsa Tsekova, Bloomberg Cross Asset Reporter.

Earnings are still in focus with FedEx, Macy's, and Lululemon all reporting in the coming days. Bloomberg's Nathan Hager previews the numbers with Denitsa Tsekova, Bloomberg Cross Asset Reporter.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. 

Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for five-minute conversations on today's biggest winners and losers in the stock market.&nbsp;
Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Week Ahead: FedEx, Macy's, Lululemon

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/91badbee-d961-4787-a8c6-b40c01370c06/transcript

Today's biggest winners and losers in the stock market, a look at the notable movers: 
On this episode of Stock Movers:

- Intuit (INTU) shares are down 7.5% in extended trading, after the tax-preparation software company gave a full-year forecast for both adjusted earnings and revenue that was weaker than expected.

- Spyre Therapeutics (SYRE) reported mixed Phase 2 results for SPY072 versus placebo in rheumatoid arthritis, with the drug meeting some but not all primary and secondary endpoints, falling short of the company’s internal bar for monotherapy development.

- Dick's Sporting Goods (DKS) shares fell after reporting second-quarter earnings, with earnings per share, revenue, and same-store sales below expectations. The company's Foot Locker division was described as an "albatross" due to structural issues, including over-dependence on a single struggling vendor and aged mall-based real estate

Today's biggest winners and losers in the stock market, a look at the notable movers: On this episode of Stock Movers: - Intuit (INTU) shares are down 7.5% in extended trading, after the tax-preparation software company gave a full-year forecast for both adjusted earnings and revenue that was weaker than expected. - Spyre Therapeutics&nbsp;(SYRE) reported mixed Phase 2 results for SPY072 versus placebo in rheumatoid arthritis, with the drug meeting some but not all primary and secondary endpoints, falling short of the company&rsquo;s internal bar for monotherapy development. - Dick's Sporting Goods (DKS) shares fell after reporting second-quarter earnings, with earnings per share, revenue, and same-store sales below expectations. The company's Foot Locker division was described as an "albatross" due to structural issues, including over-dependence on a single struggling vendor and aged mall-based real estate

 Intuit Slumps, Spyre Therapeutics Mixed, Dick's Sporting Goods Slides

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/8fc496d7-ddb9-43ae-a137-b4b1015b6e39/transcript

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:

Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostic, Emily Graffeo, Norah Mulinda, Tim Stenovec

- Moderna (MRNA) shares are up after Wolfe Research upgraded the stock to Peer Perform from Underperform without a price target. Shares surged nearly 180% to $174.38 on Aug. 19, after a late-stage trial showed a treatment combining Moderna and Merck's experimental vaccine, intismeran autogene, and Merck's Keytruda was more effective at preventing skin cancer recurrence than Keytruda alone.

- Dick's Sporting Goods (DKS) shares fell after reporting second-quarter earnings, with earnings per share, revenue, and same-store sales below expectations. The company's Foot Locker division was described as an "albatross" due to structural issues, including over-dependence on a single struggling vendor and aged mall-based real estate.

- Target (TGT) shares fell on Tuesday following criticism over a Halloween costume that sparked an apology from the company. The company removed a Halloween clown costume that critics said evoked blackface imagery, with the Chief Merchandising Officer apologizing to employees and vowing to learn from the mistake. The incident is a setback for Target, which had advanced its stock and improved results under new CEO Michael Fiddelke, and is not the company's first controversy over its products.

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostic, Emily Graffeo, Norah Mulinda, Tim Stenovec - Moderna (MRNA) shares are up after Wolfe Research upgraded the stock to Peer Perform from Underperform without a price target. Shares surged nearly 180% to $174.38 on Aug. 19, after a late-stage trial showed a treatment combining Moderna and Merck's experimental vaccine, intismeran autogene, and Merck's Keytruda was more effective at preventing skin cancer recurrence than Keytruda alone. - Dick's Sporting Goods (DKS) shares fell after reporting second-quarter earnings, with earnings per share, revenue, and same-store sales below expectations. The company's Foot Locker division was described as an "albatross" due to structural issues, including over-dependence on a single struggling vendor and aged mall-based real estate. - Target (TGT) shares fell on Tuesday following criticism over a Halloween costume that sparked an apology from the company. The company removed a Halloween clown costume that critics said evoked blackface imagery, with the Chief Merchandising Officer apologizing to employees and vowing to learn from the mistake. The incident is a setback for Target, which had advanced its stock and improved results under new CEO Michael Fiddelke, and is not the company's first controversy over its products.

Closing Bell: Moderna Gains, Dick's Sporting Goods Falls, Target Declines

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/ae84b6d6-1da1-4563-81ae-b4b1014e1557/transcript

On this episode of Stock Movers:

- TurboTax software maker Intuit (INTU) fell 3% ahead of earnings due after market close.

- Crowdstrike (CRWD) shares are experiencing downward pressure. Analysts expect CrowdStrike to report second-quarter revenue of $1.44 billion and earnings of 29 cents per share. The company's record net new ARR growth and AI-security demand are key things investors should focus on from CrowdStrike's report.

- Moderna (MRNA) shares are up after Wolfe Research upgraded the drugmaker to peerperform from underperform, citing the success of its melanoma vaccine trial.

On this episode of Stock Movers:
- TurboTax software maker Intuit (INTU) fell 3% ahead of earnings due after market close.
- Crowdstrike (CRWD) shares are experiencing downward pressure. Analysts expect CrowdStrike to report second-quarter revenue of $1.44 billion and earnings of 29 cents per share. The company's record net new ARR growth and AI-security demand are key things investors should focus on from CrowdStrike's report.
- Moderna (MRNA) shares are up after Wolfe Research upgraded the drugmaker to peerperform from underperform, citing the success of its melanoma vaccine trial.

Intuit Falls Ahead of Earnings, Crowdstrike Slides, Moderna Gains

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/b32cfb04-1a6e-43ff-a2d4-b4b1013ff595/transcript

Week Ahead: FedEx, Macy's, Lululemon

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips